Shanghai New World Co Ltd
Shanghai New World Co Ltd operates in the pharmaceuticals industry, focusing on the development, production, and sale of pharmaceutical products.
Business. Shanghai New World Co Ltd (600628.SS) is a pharmaceutical company headquartered in Shanghai, China. The firm operates within the pharmaceuticals industry, focusing on the development and sale of medical products. It is primarily listed on the Shanghai Stock Exchange. Specific details regarding operating segments or geographic revenue breakdowns are not available.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Shanghai New World Co Ltd (600628.SS) is a pharmaceutical company headquartered in Shanghai, China. The firm operates within the pharmaceuticals industry, focusing on the development and sale of medical products. It is primarily listed on the Shanghai Stock Exchange. Specific details regarding operating segments or geographic revenue breakdowns are not available.
Shanghai New World Co Ltd maintains a relatively strong liquidity position, with a current ratio of 1.6, indicating the company can cover its short-term liabilities with its short-term assets. However, the company has a negative net cash position after subtracting total debt, which raises liquidity concerns. The debt-to-equity ratio of 0.13 suggests a conservative capital structure, with limited leverage.
In terms of profitability, the company's return on equity (ROE) is 1.58%, and its return on assets (ROA) is 1.16%, both of which are below the typical thresholds for high-performing pharmaceutical firms. The net income of 66.65 million CNY and operating income of 78.94 million CNY indicate modest profitability, with a net margin of approximately 6.05%.
The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no material geographic diversification reported. This lack of diversification may expose the company to higher operational and market risks, particularly in the event of regulatory or market disruptions in its primary operating region.
Looking ahead, the company's revenue is expected to grow, with the most recent actual revenue reported at 1.04 billion CNY. However, the capital expenditure of -159.11 million CNY suggests a reduction in investment, which may impact long-term growth potential. The company's free cash flow of 15.63 million CNY is relatively low, indicating limited capacity for reinvestment or shareholder returns.
The risk assessment highlights a medium liquidity risk and a low dilution risk. The company has not disclosed any imminent plans for share issuance or dilution, and its diluted shares outstanding are equal to its basic shares, suggesting no near-term dilution pressure. However, the negative net cash position remains a concern for liquidity management.
Recent financial filings and disclosures have not revealed any material events or strategic shifts that would significantly alter the company's trajectory. The company continues to operate within its core pharmaceuticals business, with no new product lines or major partnerships disclosed in the latest available data.
- The company maintains a conservative capital structure with a low debt-to-equity ratio of 0.13.
- Return on equity and return on assets are below industry benchmarks, indicating suboptimal profitability.
- Revenue is concentrated in a single business segment, increasing exposure to market and regulatory risks.
- Free cash flow is limited, constraining the company's ability to reinvest or return value to shareholders.
- Liquidity risk is moderate, with a current ratio of 1.6, but the negative net cash position is a concern.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Shanghai New World Co Ltd Market data — financials · 2026-05-27
- Shanghai New World Co Ltd Market data — analyst estimates · 2026-05-27